{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Anti-plaque",
    "query": {
      "intervention": "Anti-plaque"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 33,
    "total_pages": 4,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Anti-plaque&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-02T17:59:10.778Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02792036",
      "title": "Intravitreal Carboplatin for the Treatment of Participants With Recurrent or Refractory Intraocular Retinoblastoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Retinoblastoma"
      ],
      "interventions": [
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Maxitrol®",
          "type": "DRUG"
        },
        {
          "name": "Focal Therapy",
          "type": "PROCEDURE"
        },
        {
          "name": "Plaque Radiotherapy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "St. Jude Children's Research Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "Up to 17 Years"
      },
      "enrollment_count": 8,
      "start_date": "2016-11-01",
      "completion_date": "2019-10-04",
      "has_results": false,
      "last_update_posted_date": "2020-02-20",
      "last_synced_at": "2026-09-02T17:59:10.778Z",
      "location_count": 1,
      "location_summary": "Memphis, Tennessee",
      "locations": [
        {
          "city": "Memphis",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02792036"
    },
    {
      "nct_id": "NCT01610596",
      "title": "A Study to Determine the Efficacy and Safety of Halobetasol Propionate Lotion 0.05% in Subjects With Plaque Psoriasis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Psoriasis",
        "Plaque Psoriasis"
      ],
      "interventions": [
        {
          "name": "Halobetasol Propionate Lotion 0.05%",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 72,
      "start_date": "2011-11",
      "completion_date": "2012-02",
      "has_results": true,
      "last_update_posted_date": "2016-05-13",
      "last_synced_at": "2026-09-02T17:59:10.778Z",
      "location_count": 3,
      "location_summary": "San Diego, California • Fridley, Minnesota • Austin, Texas",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Fridley",
          "state": "Minnesota"
        },
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01610596"
    },
    {
      "nct_id": "NCT01107457",
      "title": "A Study in Participants With Moderate to Severe Psoriasis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Psoriasis"
      ],
      "interventions": [
        {
          "name": "Ixekizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 142,
      "start_date": "2010-04",
      "completion_date": "2016-07",
      "has_results": true,
      "last_update_posted_date": "2019-09-24",
      "last_synced_at": "2026-09-02T17:59:10.778Z",
      "location_count": 31,
      "location_summary": "Bakersfield, California • New Haven, Connecticut • Washington D.C., District of Columbia + 28 more",
      "locations": [
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Miramar",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01107457"
    },
    {
      "nct_id": "NCT01384630",
      "title": "Safety, Pharmacokinetics, and Efficacy of RA-18C3 in Subjects With Moderate to Severe Psoriasis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Psoriasis"
      ],
      "interventions": [
        {
          "name": "RA-18C3",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 8,
      "start_date": "2011-09-30",
      "completion_date": "2012-08-31",
      "has_results": false,
      "last_update_posted_date": "2025-03-30",
      "last_synced_at": "2026-09-02T17:59:10.778Z",
      "location_count": 3,
      "location_summary": "Owensboro, Kentucky • Ann Arbor, Michigan • Austin, Texas",
      "locations": [
        {
          "city": "Owensboro",
          "state": "Kentucky"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01384630"
    },
    {
      "nct_id": "NCT05283135",
      "title": "High Dose Risankizumab for Psoriasis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Psoriasis"
      ],
      "interventions": [
        {
          "name": "risankizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Oregon Medical Research Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2022-03-01",
      "completion_date": "2024-07-10",
      "has_results": true,
      "last_update_posted_date": "2025-10-24",
      "last_synced_at": "2026-09-02T17:59:10.778Z",
      "location_count": 1,
      "location_summary": "Portland, Oregon",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05283135"
    },
    {
      "nct_id": "NCT00243308",
      "title": "Serp-1 for the Treatment of Acute Coronary Syndrome",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Unstable Angina",
        "Coronary Atherosclerosis",
        "Coronary Restenosis"
      ],
      "interventions": [
        {
          "name": "Serine proteinase-1 (Serp-1)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Viron Therapeutics Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 72,
      "start_date": "2005-10",
      "completion_date": "2008-12",
      "has_results": false,
      "last_update_posted_date": "2009-02-06",
      "last_synced_at": "2026-09-02T17:59:10.778Z",
      "location_count": 3,
      "location_summary": "Washington D.C., District of Columbia • Gainesville, Florida • Grand Rapids, Michigan",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00243308"
    },
    {
      "nct_id": "NCT05462106",
      "title": "A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Amyloid Plaque",
        "Beta-Amyloid",
        "DSAD",
        "Prodromal Alzheimer's Disease",
        "Alzheimer's Disease"
      ],
      "interventions": [
        {
          "name": "Placebo (Study Part 1a)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ACI-24.060 at Dose A in Study Part 1a",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ACI-24.060 at Dose B in Study Part 1a",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ACI-24.060 at Dose C in Study Part 1a",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ACI-24.060 with an additional adjuvant at Dose D in Study Part 1b",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo (Study Part 2)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ACI-24.060 at Dose A in Study Part 2",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ACI-24.060 at Dose B in Study Part 2",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ACI-24.060 at Dose C in Study Part 2",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo (Study Part 1b)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ACI-24.060 with an additional adjuvant at Dose E in Study Part 1b",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "AC Immune SA",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "35 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "35 Years to 85 Years"
      },
      "enrollment_count": 304,
      "start_date": "2022-06-21",
      "completion_date": "2029-04",
      "has_results": false,
      "last_update_posted_date": "2026-07-10",
      "last_synced_at": "2026-09-02T17:59:10.778Z",
      "location_count": 13,
      "location_summary": "Phoenix, Arizona • Lady Lake, Florida • Orlando, Florida + 9 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Lady Lake",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "The Villages",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05462106"
    },
    {
      "nct_id": "NCT07158112",
      "title": "Assessing Gingivitis and Plaque From a Marketed Toothpaste",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Gingivitis"
      ],
      "interventions": [
        {
          "name": "Stannous Fluoride Dentifrice",
          "type": "DRUG"
        },
        {
          "name": "Test Stannous Fluoride Dentifrice",
          "type": "DRUG"
        },
        {
          "name": "Sodium monofluorophosphate dentifrice",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Procter and Gamble",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 120,
      "start_date": "2025-08-30",
      "completion_date": "2025-12-07",
      "has_results": false,
      "last_update_posted_date": "2025-09-23",
      "last_synced_at": "2026-09-02T17:59:10.778Z",
      "location_count": 1,
      "location_summary": "Whitter, California",
      "locations": [
        {
          "city": "Whitter",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07158112"
    },
    {
      "nct_id": "NCT03546491",
      "title": "Evaluate Dental Plaque Benefit of a Preventive Treatment Gel",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Dental Plaque"
      ],
      "interventions": [
        {
          "name": "Preventive Gel",
          "type": "DRUG"
        },
        {
          "name": "Marketed Control",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Procter and Gamble",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 32,
      "start_date": "2018-05-08",
      "completion_date": "2018-06-22",
      "has_results": true,
      "last_update_posted_date": "2019-09-04",
      "last_synced_at": "2026-09-02T17:59:10.778Z",
      "location_count": 1,
      "location_summary": "Mason, Ohio",
      "locations": [
        {
          "city": "Mason",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03546491"
    },
    {
      "nct_id": "NCT00292396",
      "title": "Efficacy and Safety of ABT-874 in Subjects With Moderate to Severe Chronic Plaque Psoriasis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Psoriasis"
      ],
      "interventions": [
        {
          "name": "Anti IL-12 monoclonal antibody/ABT-874",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie (prior sponsor, Abbott)",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 180,
      "start_date": "2005-11",
      "completion_date": "2008-04",
      "has_results": false,
      "last_update_posted_date": "2013-01-18",
      "last_synced_at": "2026-09-02T17:59:10.778Z",
      "location_count": 16,
      "location_summary": "San Diego, California • Alpharetta, Georgia • Skokie, Illinois + 13 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Alpharetta",
          "state": "Georgia"
        },
        {
          "city": "Skokie",
          "state": "Illinois"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00292396"
    }
  ]
}